The Advanced Medical Technology Association, known as AdvaMed, has signaled a significant shift in its strategic priorities as the medical device industry grapples with an increasingly complex landscape of digital threats and shifting trade policies. Speaking at the annual MedTech Conference in Boston, AdvaMed Chairman Mick Farrell and CEO Scott Whitaker outlined a comprehensive agenda aimed at stabilizing the industry through new cybersecurity standards, proactive trade negotiations, and a push for regulatory consistency at the Food and Drug Administration. The announcement comes at a critical juncture for the sector, following a series of high-profile cyberattacks that have exposed vulnerabilities in the global healthcare infrastructure and highlighted the urgent need for a unified defensive posture among medical device manufacturers.
AdvaMed, which represents the world’s largest medical technology companies as well as hundreds of smaller innovators, is moving toward the creation of a formalized "code of ethics" regarding cybersecurity, privacy, and interoperability. According to Farrell, who also serves as the CEO of ResMed, the goal is to "raise the bar" for the entire industry. The urgency of this initiative is driven by recent headlines involving some of the biggest names in medtech. Over the past year, industry giants including Stryker and Boston Scientific faced significant operational disruptions due to cyber incidents. Other major players, such as Intuitive Surgical, Medtronic, and Abbott, have also reported varying degrees of interference from malicious actors. These breaches have served as a wake-up call, demonstrating that even the most well-funded organizations are susceptible to sophisticated digital incursions.
The proposed cybersecurity standards are intended to provide a roadmap for companies of all sizes, particularly smaller firms that may lack the robust security infrastructure of their larger peers. Farrell emphasized that while connectivity in medical devices—such as ResMed’s cloud-connected respiratory machines—offers immense benefits by giving patients real-time access to their health data, it also expands the "attack surface" for hackers. The trade group’s initiative seeks to ensure that as devices become more interconnected, the security protocols governing them become more resilient. Kirsten Tullia, AdvaMed’s executive director of digital health tech, noted that the organization has already begun facilitating forums for Chief Information Security Officers (CISOs) to share best practices and develop collaborative defense strategies. This peer-to-peer learning model is viewed as essential for staying ahead of threat actors who often target the weakest links in the supply chain.
The Evolution of the MedTech Cyber Threat Landscape
The focus on cybersecurity marks a significant evolution in the industry’s priorities. Historically, medical device manufacturers focused primarily on physical safety and clinical efficacy. However, the integration of software, cloud computing, and the Internet of Medical Things (IoMT) has introduced a new dimension of risk. Data from recent industry reports suggest that the healthcare sector is now a primary target for ransomware attacks, largely because of the sensitive nature of patient data and the critical necessity of device uptime. When a surgical robot or a monitoring system is compromised, the stakes transition from financial loss to potential patient harm.
The timeline of attacks cited during the conference underscores a troubling trend. In 2025 and 2026, the frequency of "headline-grabbing episodes" increased, prompting a realization that sporadic responses to individual attacks were no longer sufficient. AdvaMed’s push for interoperability standards is also linked to security; when devices from different manufacturers communicate within a hospital network, a lack of standardized security protocols can create backdoors for intruders. By advocating for a unified set of standards, AdvaMed hopes to create a "herd immunity" effect, where the collective security of the network is bolstered by the compliance of each individual device.
Trade Policy and the "BD Model" for Tariff Exemptions
Beyond the digital realm, AdvaMed is navigating a volatile economic environment characterized by the looming threat of tariffs and shifts in international trade relations. Scott Whitaker, CEO of AdvaMed, addressed the industry’s concerns regarding Section 232 tariffs, which are typically implemented on the grounds of national security. While the Trump administration has not yet applied these tariffs specifically to the medtech sector at large, the threat remains a significant variable for companies planning long-term capital investments.
A notable development in this area is the recent agreement between Becton, Dickinson and Company (BD) and the federal government. BD successfully negotiated a pact to expand its domestic manufacturing capabilities in the United States in exchange for an exemption from future Section 232 tariffs. Whitaker referred to this as a model that the administration appears to favor. While AdvaMed was not directly involved in BD’s specific negotiations, the trade group is closely monitoring the outcome as a potential blueprint for other member companies. The "BD Model" suggests a transactional approach to trade policy: companies that commit to bolstering U.S. industrial capacity and reducing reliance on foreign supply chains may receive preferential treatment regarding trade barriers.
Whitaker pointed out that the medtech industry already maintains a strong domestic footprint, manufacturing approximately 70% of the medical devices sold in the United States. He expressed a desire for "zero tariffs" across the sector, arguing that the industry’s contribution to national health and economic stability should be recognized. However, he also cautioned that "policymakers aren’t always consistent," necessitating a vigilant and adaptable lobbying strategy. The push for domestic manufacturing is not without its challenges, as companies must balance the higher costs of U.S.-based production with the risks of international trade disputes and supply chain vulnerabilities.
Regulatory Stability and FDA Staffing Challenges
The third pillar of AdvaMed’s current focus involves the regulatory health of the Food and Drug Administration (FDA). The ability of the industry to innovate depends heavily on the efficiency and expertise of the FDA’s Center for Devices and Radiological Health (CDRH). Whitaker highlighted the importance of maintaining adequate staffing levels and ensuring that high-quality reviewers remain at the agency. This concern follows a period of turbulence in 2025, when the administration implemented staff cuts that impacted the FDA’s capacity to process applications.
Staffing levels were a central theme in the negotiations for the latest Medical Device User Fee Amendments (MDUFA VI). These agreements, which involve the industry paying fees to the FDA to fund the review process, are predicated on the agency meeting specific performance goals, such as timelines for 510(k) clearances and Pre-Market Approvals (PMA). Whitaker emphasized that hitting hiring targets is critical to preventing backlogs that can delay life-saving technologies from reaching the market. The industry’s willingness to fund a significant portion of the FDA’s budget through user fees is tied directly to the expectation of a predictable and timely regulatory environment.
The loss of experienced reviewers is particularly concerning for the industry. As medical devices become more complex—incorporating artificial intelligence, machine learning, and advanced materials—the FDA requires specialized expertise to evaluate their safety. If the agency cannot compete with the private sector for top-tier talent, the quality and speed of reviews could suffer, ultimately stifling innovation and harming patient care. AdvaMed’s leadership remains committed to working with the FDA to ensure that the agency has the resources necessary to keep pace with the rapid technological advancements in the field.
Strategic Implications for the Future of MedTech
The dual focus on cybersecurity and trade policy reflects a broader realization within the medtech community: the era of "innovation in a vacuum" is over. Today’s medical technology companies must be as proficient in data protection and geopolitical navigation as they are in biomedical engineering. The "code of ethics" proposed by Farrell is more than just a set of technical guidelines; it is a statement of corporate responsibility in an age where digital trust is a prerequisite for clinical adoption.
For smaller medtech startups, AdvaMed’s initiatives offer a vital support system. These companies are often the engines of radical innovation but lack the legal and technical resources to defend against state-sponsored hackers or navigate complex international trade law. By creating industry-wide forums and standardized protocols, AdvaMed is effectively democratizing the tools of security and compliance.
As the MedTech Conference continues in Boston, the discussions initiated by Farrell and Whitaker are expected to resonate throughout the halls of the industry. The message is clear: the path forward requires a unified front. Whether defending against a ransomware attack or negotiating the terms of global trade, the medical device industry is moving toward a more integrated and proactive stance. The success of these efforts will likely determine the pace of medical innovation for the remainder of the decade, as companies strive to balance the benefits of a connected world with the realities of a fractured and often hostile digital and political landscape.
In conclusion, AdvaMed’s strategic pivot addresses the most pressing existential threats to the medtech sector. By championing cybersecurity standards, exploring new models for trade agreements, and advocating for a robust regulatory workforce, the organization is attempting to build a more resilient foundation for the future of healthcare. As Mick Farrell noted, the goal is to raise the bar for everyone—a necessary step in an era where the health of the patient and the security of the device are inextricably linked.
